Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Clinical experience of ceritinib in patients who progressed on alectinib is limited. In this prospective phase II study, we evaluated the activity of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase (ALK)‐rearranged metastatic (stage IIIB/IV) non‐small‐cell lung cancer (NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Hida, Toyoaki, Seto, Takashi, Horinouchi, Hidehito, Maemondo, Makoto, Takeda, Masayuki, Hotta, Katsuyuki, Hirai, Fumihiko, Kim, Young Hak, Matsumoto, Shingo, Ito, Masayuki, Ayukawa, Koichi, Tokushige, Kota, Yonemura, Masataka, Mitsudomi, Testuya, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125456/
https://www.ncbi.nlm.nih.gov/pubmed/29959809
http://dx.doi.org/10.1111/cas.13721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125456/
https://www.ncbi.nlm.nih.gov/pubmed/29959809
http://dx.doi.org/10.1111/cas.13721

Ejemplares similares